文献速递免疫规划卫生政策与健康促进

新加坡九价HPV疫苗预防宫颈癌的成本效果分析

Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
PubMed 文献 · Vaccine · 2021-03-18

本研究评估新加坡校内HPV疫苗接种项目中以九价疫苗替代二价疫苗的成本效果。采用年龄结构动态传播模型结合个体随机模拟,对13岁女孩接种两剂疫苗进行终生健康经济影响预测。结果显示九价疫苗相比二价疫苗的增量成本效果比为每获得一个质量调整生命年需S$61,629,结论认为在当前价格下九价疫苗不太可能具有成本效果。

要点

  • 九价疫苗相比二价疫苗的ICER为每QALY S$61,629。
  • 结果在合理输入值范围和疫苗保护持续时间假设下稳健。
  • 当前价格下九价疫苗在校内接种项目中不具成本效果。

核心结论

  • 鉴于较高的ICER,九价HPV疫苗相比二价疫苗在新加坡13岁女孩校内接种中不太可能具有成本效果。
  • 未来需大幅降价才能支持将九价疫苗纳入校内接种项目。

研究设计与样本

  • 采用年龄结构动态传播模型结合个体随机模拟,预测新加坡13岁女孩接种两剂九价或二价HPV疫苗的健康经济影响。
  • 从医疗系统视角估算终生时间跨度的增量成本效果比,并进行概率敏感性分析。

主要发现

  • 基础案例分析中,九价疫苗相比二价疫苗的ICER为每获得一个质量调整生命年S$61,629。
  • 结果在一系列合理输入值及疫苗保护持续时间假设下稳健。

关键数值与推荐

  • 九价疫苗对HPV-OV的交叉保护假设为96.0%,二价疫苗为22.3%。
  • 每剂疫苗价格固定为九价S$188、二价S$61.50。
  • 测试了终生和20年疫苗诱导保护两种情景。

临床怎么用

  • 为新加坡校内HPV疫苗接种项目的疫苗选择和资助决策提供经济学证据。
  • 提示在当前定价下优先使用二价疫苗可能更具成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The nonavalent human papillomavirus (HPV) vaccine has been shown to extend protection against oncogenic HPV types 31/33/45/52/58 (HPV-OV) not covered by the bivalent and quadrivalent HPV vaccines. Besides its clinical benefit, evidence on the economic value of the nonavalent vaccine is required to inform local vaccination strategies and funding decisions. This study evaluated the cost-effectiveness of replacing the bivalent vaccine with the nonavalent vaccine in the national school-based HPV vaccination programme in Singapore. METHODS: An existing age-structured dynamic transmission model coupled with stochastic individual-based simulations was adapted to project the health and economic impact of vaccinating 13-year-old girls with two doses of the nonavalent or bivalent HPV vaccines in Singapore. Direct costs (in Singapore dollars, S$) were obtained from public healthcare institutions in Singapore, while health state utilities were sourced from the literature. Incremental cost-effectiveness ratios (ICERs) were estimated over a lifetime horizon, from a healthcare system perspective. Probabilistic sensitivity analysis was performed to obtain the ICERs and corresponding variations across variable uncertainty. Particularly, this study tested the scenarios of lifelong and 20-year vaccine-induced protection, assumed 96.0% and 22.3% cross-protection against HPV-OV by nonavalent and bivalent vaccines respectively, and fixed vaccine prices per dose at S$188 for nonavalent and S$61.50 for bivalent vaccines. RESULTS: Compared with the bivalent vaccine, the use of the nonavalent vaccine was associated with an ICER of S$61,629 per quality-adjusted life year gained in the base case. The result was robust across a range of plausible input values, and to assumptions regarding the duration of vaccine protection. CONCLUSION: Given the high ICER, the nonavalent vaccine is unlikely to represent a cost-effective option compared with the bivalent vaccine for school-based HPV vaccination of 13-year old female students in Singapore. Substantial price reductions would be required to justify its inclusion in the school-based programme in the future.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Phua LC, Choi HCW, Wu J, et al. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine. 2021. PMID: 33744050. doi:10.1016/j.vaccine.2021.03.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。